BARCELONA, Spain I November 22, 2023 I La Merie Publishing released its newest product reviewing the pipeline of anti-B7-H3 immunotherapy candidates in R&D:
B7-H3-Targeted Immunotherapy Candidates Pipeline Review
Target: B7 homolog 3 protein; B7-H3; CD276
Product Category: Antibody; Cells
This product provides basic information on immunotherapy candidates in research and development targeting B7-H3.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapy candidates targeting B7-H3 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in a wide range of cancer types, including lung, prostate and esophageal, and its overexpression has been shown to correlate with poor prognosis in some cancers, making B7-H3 a promising therapeutic target. At the same time, B7-H3 is expressed at a low level in normal tissues. In malignant tissues, B7-H3 inhibits tumor antigen-specific immune responses, resulting in a protumorigenic effect. Additionally, B7-H3 promotes migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and affects tumor cell metabolism.
There are no B7-H3 directed medicines approved for the treatment of any cancer, but a number of effector-enhanced B7-H3-targeted immunotherapy candidates in preclinical and clinical development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models.
The report “B7-H3-Targeted Immunotherapy Candidates Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/b7-h3-targeted-immunotherapy-candidates-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 232
BARCELONA, Spain I November 22, 2023 I La Merie Publishing released its newest product reviewing the pipeline of anti-B7-H3 immunotherapy candidates in R&D:
B7-H3-Targeted Immunotherapy Candidates Pipeline Review
Target: B7 homolog 3 protein; B7-H3; CD276
Product Category: Antibody; Cells
This product provides basic information on immunotherapy candidates in research and development targeting B7-H3.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapy candidates targeting B7-H3 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in a wide range of cancer types, including lung, prostate and esophageal, and its overexpression has been shown to correlate with poor prognosis in some cancers, making B7-H3 a promising therapeutic target. At the same time, B7-H3 is expressed at a low level in normal tissues. In malignant tissues, B7-H3 inhibits tumor antigen-specific immune responses, resulting in a protumorigenic effect. Additionally, B7-H3 promotes migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and affects tumor cell metabolism.
There are no B7-H3 directed medicines approved for the treatment of any cancer, but a number of effector-enhanced B7-H3-targeted immunotherapy candidates in preclinical and clinical development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models.
The report “B7-H3-Targeted Immunotherapy Candidates Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/b7-h3-targeted-immunotherapy-candidates-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 232
